Abstract
Long QT syndrome (LQTS) is a potentially lethal, yet treatable genetic heart disease for which left cardiac sympathetic denervation (LCSD) is a class I recommendation by the ACC, AHA, and HRS as either a treatment intensifier for severe disease or a treatment alternative for side effects to standard drug therapy. Recent reports suggest bilateral CSD (BiCSD) as the initial surgical denervation therapy in LQTS.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
